Companies · Biotech

Ångström AISummer 2024Active

San Francisco · CA, USA · Biotech · founded 2024 · https://www.angstrom-ai.com

Diligence memoA one-page analyst read on Ångström AI — recommendation, valuation, rhythm, risks.
Total raised · real
0
Rounds
Latest step-up
Top 34%
Sector rank · raised
Latest stage · inferred

Ångström AI: limited disclosed financing to assess.

Synthesized from the figures below est. — every claim rests on a number shown on this page.

Where it sits in Biotech

Ångström AI is one of 233 Biotech companies tracked from San Francisco, CA, USA, on record since 2024. By capital raised it ranks mid-pack (ahead of 67% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%

operates a technology-led product inferred from public copy

Grounded in: “You are a venture analyst

Gen AI molecular simulations that reproduce wetlab results

Angstrom AI builds GenAI-based molecular simulations to substitute wet lab experiments in the pre-clinical drug development pipeline. We are a team of 2 PhD's and 2 Professors from the University of Cambridge who decided to start a company together after we realised how to combine breakthoughs in our research in quantum-accurate models of physics and generative AI models. Our Biotech/Pharma clients can verify the efficacy and safety of new drug candidates using our computer simulations, which match the accuracy of wet lab experiments, but are over 100x faster. We achieve this accuracy by constraining our genAI-based simulations to obey the laws of physics, avoiding the hallucinations seen in other GenAI technologies. Since joining YC, Angstrom AI has developed the first physically accurate gen-AI based simulation of multiple molecules interacting. We have published the first molecule water solubility results with accuracy within the error range of wet lab experiments. We have also kicked-off a 150K pilot project with a pharma company to apply our tech to estimating solubility in their drug development pipeline.

AIAI-powered Drug DiscoveryArtificial IntelligenceBiotechDrug discoveryai/mlbiotechpharma
Find Ångström AI online

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

No round amounts on record to chart.

Financing ladder & sequence gaps

No staged rounds to sequence.

Modeled valuation trajectory
Base estimate est.
Conservative case
Upside case
Modeled post-money

Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Financing rhythm
Avg between rounds
Capital velocity
On record since
First round
0
Rounds on file
How it compares to the market

Benchmarked against 233 companies in Biotech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages)
This company
Sector median$7.8M
Modeled value — vs sector median (estimate, all stages)
This company
Sector median$56.2M

Raised more than 67% of sector peers (real $). Modeled value above 67% of peers (estimate).

Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
No rounds recorded.
Intelligence
Modeled next raise
Modeled next size est.
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Registry & provenance

Ångström AI is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
10x ScienceBiotechsame sector
1849 bioBiotechsame sector
1910Biotechsame sector
20nBiotechsame sector
54Gene, Inc.BiotechSeries B$48.3M$599.1Msame sector
Abacus Bioscience Inc.BiotechSeries A$4.4M$46.6Msame sector
Abalone BioBiotechsame sector
Acoustic Wave Cell Therapy, Inc.BiotechSeries A$20.5M$85.0Msame sector
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
10x Science
The AI-native platform for next-generation protein characterization.
Biotech82%
b12 Labs
Chemical Copilot for Pharma and Biotech
Biotech78%
Angstrom Bio, Inc.BiotechnologySeed$81.6M78%
Medium Biosciences
AI-designed Affinity Reagents
Biotech78%
Convexia
The world's first AI-maximalist pharma company
Biotech78%
Gen1E Lifesciences Inc.
AI platform accelerating therapies for rare & inflammatory diseases.
BiotechnologySeries B$22.5M78%
Scoop
Automating regulatory submissions for life sciences
Biotech78%
Nabla Bio
We use AI to design antibodies for intractable diseases
Biotech78%
Frequently asked
What does Ångström AI do and where is it based?
Ångström AI operates in the Biotech sector, based in San Francisco, CA, USA. Gen AI molecular simulations that reproduce wetlab results
Explore related

See where Ångström AI sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Ångström AI, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.